Heart Failure Outcomes

Is there Really a Clinical Benefit to Using the New Drugs for HFrEF in Real Life

by Prateek Chopra | May 28, 2026 | Cardiology Conferences | ESC-HF 2026 Since 2017, several new therapies demonstrating clinical benefit in patients with HF and reduced left LVEF have been approved for clinical use. However, real-world evidence regarding the benefits of these therapies remains limited. The study aimed to analyse the characteristics and prognosis of patients with HFrEF prospectively followed […]

Is there Really a Clinical Benefit to Using the New Drugs for HFrEF in Real Life Read Post »

Leave a Comment / ESC-HF Day 3 / bluetree.healthcare@gmail.com / July 30, 2026 / Guideline-Directed Medical Therapy (GDMT), Heart Failure Outcomes, Heart Failure with Reduced Ejection Fraction (HFrEF), SGLT2 Inhibitors

Latest Analyses in HFrEF, Diagnosis, Pa ent Selec on, and Clinical Experience

by Prateek Chopra | May 24, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure with reduced ejection fraction (HFrEF) continues to be associated with substantial morbidity and mortality despite significant advances in therapeutic options. In the era of guideline-directed medical therapy (GDMT), a growing body of evidence has highlighted the importance of accurate diagnosis, early patient identification, and timely initiation

Latest Analyses in HFrEF, Diagnosis, Pa ent Selec on, and Clinical Experience Read Post »

Leave a Comment / ESC-HF Day 2 / bluetree.healthcare@gmail.com / July 30, 2026 / Guideline-Directed Medical Therapy (GDMT), Heart Failure Diagnosis, Heart Failure Outcomes, Heart Failure with Reduced Ejection Fraction (HFrEF), Personalized Heart Failure Management

Type 2 Diabetes and Chronic Kidney Disease Combina ons in Heart Failure Acrossthe Ejec on Frac on Spectrum: Clinical Associa ons, Medica on Use, andCause-Specific Outcomes

by Prateek Chopra | May 18, 2026 | Cardiology Conferences | ESC-HF 2026 Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) frequently coexist with Heart Failure (HF), substantially increasing the risks of mortality and hospitalization for HF (HHF). Several HF therapies have demonstrated cardiorenal benefits in patients with CKD and/or T2DM; however, real-world evidence suggests that these therapies remain

Type 2 Diabetes and Chronic Kidney Disease Combina ons in Heart Failure Acrossthe Ejec on Frac on Spectrum: Clinical Associa ons, Medica on Use, andCause-Specific Outcomes Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiorenal Syndrome, Guideline-Directed Medical Therapy (GDMT), Heart Failure and Chronic Kidney Disease (CKD), Heart Failure Outcomes, Type 2 Diabetes (T2DM)